Acrivon Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
ACRV$1.61+2.5%Stored close · as of Nov 6, 2026
Contents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Acrivon Therapeutics, Inc. | ||
| Date: May 14, 2024 | By: | /s/ Peter Blume-Jensen |
|---|---|---|
| Peter Blume-Jensen, M.D., Ph.D. | ||
| Chief Executive Officer and President | ||
| (Principal Executive Officer) | ||
| Date: May 14, 2024 | By: | /s/ Rasmus Holm-Jorgensen |
|---|---|---|
| Rasmus Holm-Jorgensen | ||
| Chief Financial Officer | ||
| (Principal Financial Officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.